Efficacy and Tolerability of Gefapixant for Treatment of Refractory or Unexplained Chronic Cough: A Systematic Review and Dose-Response Meta-Analysis.

Elena Kum,Matthew Patel,Nermin Diab,Mustafaa Wahab,Dena Zeraatkar,Derek K Chu,Paul M O'Byrne,Gordon H Guyatt,Imran Satia

JAMA（2023）

引用 0|浏览17

暂无评分

摘要

Compared with placebo, gefapixant (45 mg orally twice daily) led to modest improvements in cough frequency, cough severity, and cough-specific quality of life but increased taste-related adverse events.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要